DNMT3A-dCas9 Citations (5)
Originally described in: dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.O'Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, Mackay JP, Farnham PJ, Segal DJ Nucleic Acids Res. 2017 Sep 29;45(17):9901-9916. doi: 10.1093/nar/gkx578. PubMed Journal
Articles Citing DNMT3A-dCas9
| Articles |
|---|
Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H, Bates SL, Carter SS, Nisson KA, Halmai J, Fink KD, Rhie SK, Farnham PJ, Segal DJ.
Epigenetics Chromatin. 2019 May 3;12(1):26. doi: 10.1186/s13072-019-0275-8.
PubMed
Associated Plasmids |
| Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. Deutschmeyer V, Breuer J, Walesch SK, Sokol AM, Graumann J, Bartkuhn M, Boettger T, Rossbach O, Richter AM. Clin Epigenetics. 2019 Dec 4;11(1):182. doi: 10.1186/s13148-019-0774-2. PubMed |
| Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing. O'Geen H, Tomkova M, Combs JA, Tilley EK, Segal DJ. Nucleic Acids Res. 2022 Apr 8;50(6):3239-3253. doi: 10.1093/nar/gkac123. PubMed |
| Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. Woods ML, Weiss A, Sokol AM, Graumann J, Boettger T, Richter AM, Schermuly RT, Dammann RH. Cancer Gene Ther. 2022 Dec;29(12):1975-1987. doi: 10.1038/s41417-022-00513-x. Epub 2022 Jul 28. PubMed |
| Dual-Luciferase Reporter Assay for Prescreening CRISPR (d)Cas9-Mediated Epigenetic Editing on a Plant Promoter Using Human Cells. Hinrichs AK, Koch A, Richter AM. Methods Mol Biol. 2024;2788:273-285. doi: 10.1007/978-1-0716-3782-1_16. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.